News
Boost to Enhertu's prospects as FDA clears Roche diagnostic
Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.
Wednesday 16 April 2025
